Pharmacological Therapy for Influenza Recovery in Patients with Underlying Respiratory Conditions

Primary Recommendation

The Centers for Disease Control and Prevention recommends oseltamivir 75 mg orally twice daily for 5 days as the primary antiviral therapy for patients with asthma or COPD who have influenza, while zanamivir is not recommended due to significant risk of bronchospasm and lack of proven efficacy in this population 1, 2, 3

The American Thoracic Society recommends initiating oseltamivir within 48 hours of symptom onset for optimal benefit, but hospitalized or severely ill patients may benefit even beyond 48 hours 5, 6
The Centers for Disease Control and Prevention recommends reducing the dose of oseltamivir to 75 mg once daily if creatinine clearance is less than 30 mL/min 4, 5
The World Health Organization recommends taking oseltamivir with food to minimize nausea and vomiting 1, 2, 3

The Global Initiative for Chronic Obstructive Lung Disease recommends adding systemic corticosteroids, such as prednisone 40 mg daily for 5 days, to improve lung function, oxygenation, and shorten recovery time 4
The American College of Chest Physicians recommends using short-acting β2-agonists with or without short-acting anticholinergics as first-line bronchodilator therapy 4

The Infectious Diseases Society of America recommends co-amoxiclav as the first-line antibiotic for secondary bacterial infections, with doxycycline as an alternative for β-lactam intolerance 4, 5, 6, 7

The British Thoracic Society recommends maintaining a target SpO2 of at least 92% and using controlled oxygen with repeated arterial blood gas monitoring to avoid CO2 retention in COPD patients 4, 6

The American Thoracic Society recommends calculating the CURB-65 score immediately and checking vital signs at least twice daily 4, 6
The Society of Critical Care Medicine recommends transferring patients to the ICU if they develop severe respiratory distress, progressive hypercapnia, or septic shock 4, 6

The Centers for Disease Control and Prevention reports that oseltamivir can reduce symptom duration by 24-53.9 hours and symptom severity by up to 38% 4, 5
The World Health Organization reports that oseltamivir can reduce complications, such as secondary infections, and decrease antibiotic use and hospitalizations 5